Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
Novo Nordisk's Older Weight Loss Drug May Slow Cognitive Decline in Alzheimer's Patients, Small Study Shows Brain-Protecting Benefits
A Phase 2b clinical trial presented at the Alzheimer's Association International Conference (AAIC) 2024 reveals that Novo Nordisk A/S's (NYSE:NVO) older generation GLP-1 drug, liraglutide, may slow cognitive decline by protecting the brain.
2024年在阿尔茨海默病国际协会年会上报道的20亿期三期临床试验表明，诺和诺德（纽交所代码：NVO）的老一代GLP-1药物利拉鲁肽可以通过保护大脑减缓认知衰退。
Related: Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds.
相关新闻：诺和诺德的奥塞米匹（Ozempic）可以减少糖尿病病人吸烟相关的健康干预措施。
GLP-1 (Glucagon-Like Peptide-1) drugs are a class of medications primarily used to treat type 2 diabetes and, in some cases, obesity.
GLP-1（胰高糖素样肽-1）药物是一类主要用于治疗2型糖尿病，以及在某些情况下用于治疗肥胖症的药物。
GLP-1 receptor agonists mimic the natural hormone glucagon-like peptide and help manage diabetes, promote weight loss, and reduce heart disease, stroke, and kidney disease risks.
GLP-1受体激动剂模拟天然荷尔蒙胰高糖素样肽，有助于管理糖尿病、促进体重减轻，并降低心脏病、中风和肾病的风险。
Animal studies indicate these drugs may also have neuroprotective effects, reducing early forms of amyloid and normalizing brain glucose processing.
动物研究表明，这些药物也可能具有神经保护作用，减少淀粉样蛋白的早期形式并正常化大脑葡萄糖处理。
The study included 204 patients with mild Alzheimer's across 24 UK clinics. Participants received up to 1.8 mg of liraglutide or a daily placebo for a year.
研究包括来自24家英国诊所的204名轻度阿尔茨海默病患者，参与者每天接受1.8毫克利拉鲁肽或每天一次的安慰剂治疗一年。
The primary endpoint, change in cerebral glucose metabolic rate (an assessment of brain function), was not met. However, significant benefits were observed in secondary endpoints like clinical and cognitive measures and brain volume changes.
主要终点——大脑葡萄糖代谢率的变化（大脑功能的一项评估）未达标。但在临床和认知评估以及大脑体积变化等二级终点上观察到显著的益处。
Those on liraglutide experienced almost 50% less brain volume loss in critical regions such as the frontal, temporal, and parietal lobes.
那些服用利拉鲁肽的人在关键区域，如额叶、颞叶和枕叶，脑部体积减少量几乎减少了50％。
Cognitive testing before and after treatment showed an 18% slower decline in cognitive function among those on liraglutide compared to the placebo group.
治疗前后的认知功能测试显示，在利拉鲁肽组中，认知功能的下降速度比安慰剂组慢18％。
Cognitive function was measured using a composite score from 18 different tests. The study also reported gastrointestinal issues, such as nausea, as the most common side effects, but serious side effects were relatively rare.
认知功能是使用18个不同测试的综合得分来衡量的。该研究还报告了胃肠问题（如恶心）作为最常见的副作用，但严重副作用相对较少。
Further research is warranted, but current late-stage trials of GLP-1 analogs, like the EVOKE Plus trial of semaglutide, are well-positioned to explore these findings further.
有待进一步研究，但目前的GLP-1类似物后期试验（例如塞格露肽（semaglutide）的EVOKE Plus试验）已经有了很好的探索这些发现的位置。
Reuters noted that its two trials began in 2021 and results are expected in 2025.
路透社指出，其两次试验始于2021年，结果预计将于2025年发布。
Liraglutide, marketed as Saxenda for weight loss and Victoza for diabetes, has already been approved by the FDA.
利拉鲁肽作为用于减轻体重的Saxenda和治疗糖尿病的Victoza已经获得FDA批准。
Price Action: NVO stock is up 0.50% at $128.69 at the last check on Tuesday.
价格走势：NVO股票在周二的最后一次查询时上涨0.50％，为128.69美元。
- Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off.
- 贝克与迪金森（Becton Dickinson）分拆后，胰岛素装置制造商Embecta考虑出售，股价下跌70％。
Photo via Shutterstock
图片来自shutterstock。